PEP enters the final stretch before its October 8 earnings call with options traders now running their most defensive posture in months — a signal that has grown sharper since last week's note, even as the stock found a brief footing on Tuesday.
The options market is the loudest voice in the room right now. The put/call ratio climbed to 0.60 on Monday and held near that level Tuesday, more than two and a half standard deviations above its 20-day average of 0.49. That z-score of 2.56 is a meaningful escalation from the 1.94 reading flagged in the previous note — protection demand has not eased, it has intensified. The PCR has not been this elevated relative to its own recent history for the better part of the year; the 52-week high sits at 1.36, so the absolute level is not extreme, but the rate of change is. Investors are paying more for downside coverage than they were even a week ago, and they are doing so against a stock that has now given back 8.6% across the past month and is down just over 3% this week, closing at $131.19 after a modest 1.2% bounce Tuesday.
The borrow market, by contrast, stays firmly in the background. Availability is essentially unlimited — billions of shares remain available to lend, with no meaningful change from last week. Cost-to-borrow has doubled on the week to 0.44%, but that figure is still negligibly low in absolute terms, typical of a mega-cap name with no real squeeze dynamic. Short interest is a non-story: 1.56% of the free float, down more than 26% over the past month as former shorts have covered. The ORTEX short score of 31.0 has barely moved in two weeks. The positioning picture splits cleanly: shorts are not building, but options hedgers are getting more active. The relevant pressure is coming from longs protecting gains — or managing risk into a number.
The Street has grown more cautious in a way that corroborates the options mood. Today, BNP Paribas lowered its target from $183 to $161 while holding its Outperform rating — a 12% trim that reflects a softer fundamental backdrop rather than a change in directional conviction. That follows a wave of cuts in mid-July, when Citigroup downgraded outright from Buy to Neutral and Morgan Stanley, Wells Fargo, Jefferies, and TD Cowen all trimmed targets by 10-15% after the prior earnings release. The consensus mean target now sits at $152.65, implying roughly 16% upside to Tuesday's close — respectable on paper, but the direction of travel has been consistently lower. Valuation has compressed alongside the price: the P/E has shed 1.6 turns across 30 days and price-to-book has dropped by 0.78 turns, reflecting both the lower stock price and muted earnings momentum. EPS momentum scores rank in the 37th percentile over 90 days, and the forward earnings growth estimate is deeply negative — details consistent with the bear case centred on input cost pressure and weak North American snack volumes.
Bulls point to PepsiCo's international diversification as a buffer, with Asia-Pacific, EMEA, and Latin America all holding up better than the domestic business. The Q2 earnings beat in late July backed that view: the stock jumped 3.6% the day of the release and held most of that gain over the following week. The October 8 print carries a different setup, though — the stock is more than 8% softer than it was at the July release, and the options market is already bracing. The bear case flags slow top-line growth, margin pressure, and sustained weakness in the convenience-channel snack business as the drags most likely to weigh on guidance.
Peer context does not offer PepsiCo much cover. KO is essentially flat on the week, down just 0.1%, and CCEP has held its own at -0.4%. TAP, which shares some consumer exposure overlap, dropped a steeper 6.1% on the week — so the divergence between PEP and pure beverage peers is narrowing, but PepsiCo's underperformance over a longer window remains a company-specific story tied to snack volumes and North American consumer fatigue.
The next meaningful read comes October 8. Until then, the tension to monitor is whether the PCR holds above the 0.60 level and whether target cuts continue to revise the consensus lower — each of those would suggest the market is treating the upcoming print as a downside risk event rather than a recovery catalyst.
See the live data behind this article on ORTEX.
Open PEP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
